Patritumab deruxtecan for previously treated metastatic or locally advanced EGFR mutated non-small-cell lung cancer

Patritumab deruxtecan is currently in clinical development for treatment of metastatic or locally advanced epidermal growth factor receptor-mutated (EGFRm) non-squamous non-small cell lung cancer (NSCLC) after failure of several therapy options. NSCLC is the most common type of lung cancer. EGFR is protein involved in the growth and division of healthy cells. For some NSCLC sufferers, there is a mutation to the gene coding for this protein which means it can be significantly over expressed. This can cause cells to grow out of control and lead to cancer. The most common symptoms of lung cancer include cough, breathlessness, coughing up phlegm with blood, pain in the chest or shoulder, recurrent chest infections, loss of appetite, weight loss and fatigue.